Piper Sandler Maintains Overweight on Revance Therapeutics, Lowers Price Target to $20
Portfolio Pulse from Benzinga Newsdesk
Piper Sandler analyst David Amsellem has maintained an Overweight rating on Revance Therapeutics (RVNC) but has lowered the price target from $42 to $20.
February 29, 2024 | 1:43 pm
News sentiment analysis
Sort by:
Ascending
NEGATIVE IMPACT
Piper Sandler maintains an Overweight rating on Revance Therapeutics but lowers the price target from $42 to $20.
The reduction in price target by Piper Sandler from $42 to $20, despite maintaining an Overweight rating, could lead to a negative short-term impact on RVNC's stock price. This significant decrease in the price target may shake investor confidence and lead to a bearish outlook in the short term.
CONFIDENCE 90
IMPORTANCE 90
RELEVANCE 100